This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
Responses to the survey are due by 20 March 2013.
ISPE initially announced the survey in mid-February as part of its Drug Shortage Initiative, a global effort led by a task force of industry leaders with review and input by leading global health authorities and related organizations. ISPE launched this initiative in support of the pharmaceutical industry and global health authorities' efforts to understand and address the complex and critical issue of drug shortages. The survey is designed to collect data on the technical, scientific, manufacturing, quality and compliance issues that may have resulted in drug shortages.
"We are reaching out to pharmaceutical professionals and ISPE Members who have had experience dealing with technical, quality and manufacturing issues related to drug shortages, as well as those who have worked to avoid a shortage or who have never experienced a shortage but have been personally affected by a shortage situation," said ISPE President and CEO Nancy S. Berg. "This much-needed technical data will yield new insights into a critical global health issue."
ISPE is encouraging responses from both individuals and companies. Survey responses will be completely anonymous, and all data will be tabulated by a third-party firm. Results are expected to be announced and discussed at ISPE's Redefining the "C" in "CGMP" Conference in Baltimore, Md. USA, 11 – 13 June 2013.
For more information on this important initiative, please visit www.ISPE.org/DrugSurveyDetails.
